Quick Answer
Actinium Pharmaceuticals, Inc. reported Diluted EPS of $1.09 per share (loss) for fiscal year 2025.
Actinium Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.09 | +14.2% |
| 2024 | -$1.27 | +30.6% |
| 2023 | -$1.83 | -33.6% |
| 2022 | -$1.37 | -14.2% |
| 2021 | -$1.20 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.16 | +56.8% | +27.3% |
| June 30, 2025 | -$0.22 | +42.1% | +56.9% |
| March 31, 2025 | -$0.51 | -64.5% | -37.8% |
| September 30, 2024 | -$0.37 | +24.5% | +2.6% |
| June 30, 2024 | -$0.38 | +34.5% | -22.6% |
| March 31, 2024 | -$0.31 | +27.9% | +36.7% |
| September 30, 2023 | -$0.49 | -28.9% | +15.5% |
| June 30, 2023 | -$0.58 | -75.8% | -34.9% |
- Actinium Pharmaceuticals, Inc. showed an increase of +14.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Actinium Pharmaceuticals, Inc.’s diluted eps has grown by 9.2% (from $1.20 per share (loss) to $1.09 per share (loss)).
- The most recent figure is from Actinium Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: